Pulmonary Embolism: Mechanism and Therapeutic Innovation

Completed

• Conditions: Pulmonary Embolism

• Registration Number: NCT05360992
• Lead Sponsor: China National Center for Cardiovascular Diseases

Brief Summary

To explore the pathogenesis, therapy and outcome of pulmonary embolism (PE) and chronic thromboembolic pulmonary hypertension (CTEPH).

Detailed Description

The study recruited consecutive outpatients or hospitalized patients diagnosed with pulmonary embolism (PE cohort) and chronic thromboembolic pulmonary hypertension (CTEPH cohort). The follow-up of all patients was performed annually by phone or outpatient visit. The main outcomes were bleeding, recurrent events, and survival. The objective of the study was to explore the pathogenesis, therapy and outcome of PE and CTEPH.

Study Timeline

• Study Start: 2017-01-01
• Primary Completion: 2021-10-13
• Study Completion: 2021-10-13
• Status Verified: 2022-04
• Study First Submitted: 2022-04-27
• Study First Submitted QC: 2022-04-29
• Last Update Submitted: 2022-04-29
• Study First Posted: 2022-05-04
• Last Update Posted: 2022-05-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1200

Inclusion Criteria

• All hospitalized patients or outpatients diagnosed with PE or CTEPH;
• Age ≥18.

Exclusion Criteria

• Refused informed consents.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Bleeding Rate of Patients	through study completion, an average of 1 year.	Events were recored by follow-up.
Survival Rate of Patients	through study completion, an average of 1 year.	Events were recored by follow-up.
Recurrent Incidence of Patients	through study completion, an average of 1 year.	Recurrent PE was measured by computed tomography pulmonary angiography (CTPA) or ventilation/perfusion (V/Q) lung scans. Recurrent deep venous thrombosis was measured by lower extremity Doppler ultrasound.